IT1405793B1 - Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica - Google Patents

Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica

Info

Publication number: IT1405793B1
Authority: IT; Italy
Prior art keywords: gene; molecule; modified human; u1snrna; human u1snrna
Prior art date: 2010-10-15

Application number

ITTO2010A000840A

Other languages

English (en)

Inventor

Franco Pagani

Mirko Pinotti

Original Assignee

Univ Ferrara

I C G E B Internat Ct For Genetic Engineering And Biotechnology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-15

Filing date

2010-10-15

Publication date

2014-01-24

2010-10-15 Priority to ITTO2010A000840A priority Critical patent/IT1405793B1/it

2010-10-15 Application filed by Univ Ferrara, I C G E B Internat Ct For Genetic Engineering And Biotechnology filed Critical Univ Ferrara

2011-10-14 Priority to EP11799816.1A priority patent/EP2627339B1/en

2011-10-14 Priority to PCT/IB2011/054573 priority patent/WO2012049665A1/en

2011-10-14 Priority to BR112013008759A priority patent/BR112013008759A2/pt

2011-10-14 Priority to ES11799816.1T priority patent/ES2545815T3/es

2011-10-14 Priority to CN201180049740.9A priority patent/CN103314106B/zh

2011-10-14 Priority to JP2013533322A priority patent/JP5985487B2/ja

2011-10-14 Priority to RU2013122109/10A priority patent/RU2013122109A/ru

2011-10-14 Priority to US13/878,355 priority patent/US9074207B2/en

2012-04-16 Publication of ITTO20100840A1 publication Critical patent/ITTO20100840A1/it

2014-01-24 Application granted granted Critical

2014-01-24 Publication of IT1405793B1 publication Critical patent/IT1405793B1/it

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
- C12Y306/03049—Channel-conductance-controlling ATPase (3.6.3.49)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Virology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ITTO2010A000840A 2010-10-15 2010-10-15 Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica IT1405793B1 (it)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
ITTO2010A000840A IT1405793B1 (it)	2010-10-15	2010-10-15	Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica
PCT/IB2011/054573 WO2012049665A1 (en)	2010-10-15	2011-10-14	A modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy
BR112013008759A BR112013008759A2 (pt)	2010-10-15	2011-10-14	molécula u1snrna humana modificada, um gene codificando para a molécula u1snrna humana modificada, um vetor de expressão incluindo o gene, e uso dos mesmos em terapia de gene
ES11799816.1T ES2545815T3 (es)	2010-10-15	2011-10-14	Molécula de ARNnpU1 humana modificada, gen que codifica para la molécula de ARNnpU1 humana modificada, vector de expresión que incluye el gen y el uso del mismo en terapia génica
EP11799816.1A EP2627339B1 (en)	2010-10-15	2011-10-14	A modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy
CN201180049740.9A CN103314106B (zh)	2010-10-15	2011-10-14	修饰的人类U1snRNA分子、编码修饰的人类U1snRNA分子的基因、包括该基因的表达载体及其在基因治疗中的用途
JP2013533322A JP5985487B2 (ja)	2010-10-15	2011-10-14	改変ヒトＵ１ｓｎＲＮＡ分子、改変ヒトＵ１ｓｎＲＮＡ分子をコードしている遺伝子、遺伝子を含む発現ベクターおよび遺伝子治療におけるその使用
RU2013122109/10A RU2013122109A (ru)	2010-10-15	2011-10-14	МОДИФИЦИРОВАННАЯ МОЛЕКУЛА U1мяРНК ЧЕЛОВЕКА, ГЕН, КОДИРУЮЩИЙ МОДИФИЦИРОВАННУЮ МОЛЕКУЛУ U1мяРНК ЧЕЛОВЕКА, ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГЕН, И ИХ ПРИМЕНЕНИЕ В ГЕННОЙ ТЕРАПИИ
US13/878,355 US9074207B2 (en)	2010-10-15	2011-10-14	Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITTO2010A000840A IT1405793B1 (it)	2010-10-15	2010-10-15	Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica

Publications (2)

Publication Number	Publication Date
ITTO20100840A1 ITTO20100840A1 (it)	2012-04-16
IT1405793B1 true IT1405793B1 (it)	2014-01-24

Family

ID=43738379

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ITTO2010A000840A IT1405793B1 (it)	2010-10-15	2010-10-15	Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica

Country Status (9)

Country	Link
US (1)	US9074207B2 (it)
EP (1)	EP2627339B1 (it)
JP (1)	JP5985487B2 (it)
CN (1)	CN103314106B (it)
BR (1)	BR112013008759A2 (it)
ES (1)	ES2545815T3 (it)
IT (1)	IT1405793B1 (it)
RU (1)	RU2013122109A (it)
WO (1)	WO2012049665A1 (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3699284B1 (en) *	2012-07-05	2024-11-06	The Trustees of the University of Pennsylvania	U1 snrnp regulates gene expression and modulates oncogenicity
WO2015036552A1 (en) *	2013-09-12	2015-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of cystic fibrosis
US9669109B1 (en)	2015-11-24	2017-06-06	Universita Di Ferrara	Modified human U1snRNA molecule, a gene encoding for the modified human U1snRNA molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy
PL3534922T3 (pl)	2016-11-04	2024-08-19	Takeda Pharmaceutical Company Limited	Preparaty wirusa związanego z adenowirusem
CN109486813B (zh) *	2018-10-10	2022-01-18	广州医科大学附属第二医院	一种用于修复TPP1基因Pre-mRNA异常剪接的U1-snRNA及其应用
CN119552865A (zh) *	2019-07-23	2025-03-04	牛津生物医学（英国）有限公司	慢病毒载体的优化生产
CN113444722B (zh) *	2020-03-24	2024-09-24	中国科学院脑科学与智能技术卓越创新中心	单碱基编辑介导的剪接修复在制备治疗脊髓性肌萎缩症中的应用
CN114457072B (zh) *	2021-04-19	2023-08-15	苏州系统医学研究所	一种具有抗病毒活性的多核苷酸及其用途
MX2024002647A (es) *	2021-09-03	2024-05-10	Tacit Therapeutics Inc	Edición de arn a través del reclutamiento de componentes de espliceosomas.
US20230279397A1 (en)	2022-03-04	2023-09-07	Locanabio, Inc.	Compositions and methods comprising engineered short nuclear rna (snrna)
WO2023240236A1 (en)	2022-06-10	2023-12-14	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of spinal muscular atrophy related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020058287A1 (en) *	2000-03-10	2002-05-16	Whitehead Institute For Biomedical Research	Novel small nuclear RNA vectors and uses therefor
US7838657B2 (en) *	2004-12-03	2010-11-23	University Of Massachusetts	Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
DK1910395T3 (da) *	2005-06-23	2013-02-04	Isis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulation af SMN2-splejsning

2010
- 2010-10-15 IT ITTO2010A000840A patent/IT1405793B1/it active
2011
- 2011-10-14 US US13/878,355 patent/US9074207B2/en not_active Expired - Fee Related
- 2011-10-14 EP EP11799816.1A patent/EP2627339B1/en active Active
- 2011-10-14 WO PCT/IB2011/054573 patent/WO2012049665A1/en not_active Ceased
- 2011-10-14 BR BR112013008759A patent/BR112013008759A2/pt not_active Application Discontinuation
- 2011-10-14 RU RU2013122109/10A patent/RU2013122109A/ru not_active Application Discontinuation
- 2011-10-14 ES ES11799816.1T patent/ES2545815T3/es active Active
- 2011-10-14 JP JP2013533322A patent/JP5985487B2/ja not_active Expired - Fee Related
- 2011-10-14 CN CN201180049740.9A patent/CN103314106B/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2012049665A1 (en)	2012-04-19
CN103314106B (zh)	2017-09-12
CN103314106A (zh)	2013-09-18
US9074207B2 (en)	2015-07-07
ITTO20100840A1 (it)	2012-04-16
ES2545815T3 (es)	2015-09-16
EP2627339B1 (en)	2015-05-27
JP2014501493A (ja)	2014-01-23
BR112013008759A2 (pt)	2016-06-28
US20130210902A1 (en)	2013-08-15
EP2627339A1 (en)	2013-08-21
JP5985487B2 (ja)	2016-09-06
RU2013122109A (ru)	2014-11-20

Publication	Publication Date	Title
IT1405793B1 (it)	2014-01-24	Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica
FIC20240036I1 (fi)	2024-10-29	Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L
IL264200B (en)	2022-05-01	Flexible cushioning pads, items incorporating such pads, and methods of making and using
CO6791606A2 (es)	2013-11-14	Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
IL231536A (en)	2016-09-29	Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
HUE037082T2 (hu)	2018-08-28	Új lipidek és készítmények terápiás hatóanyagok szállítására
IL216006A (en)	2015-03-31	Substituted aromatic compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medications
IL221160A (en)	2015-09-24	4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
SI2935303T1 (sl)	2021-08-31	4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
BR112012031194A2 (pt)	2018-05-29	derivados de cisteamina e seu uso no tratamento de ehna
IL232325A0 (en)	2014-06-30	18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
CO6950473A2 (es)	2014-05-20	Novedosos derivados de purina y su uso en el tratamiento de enfermedades
TN2012000414A1 (en)	2014-01-30	Forms of rifaximin and uses thereof
HUE049886T2 (hu)	2020-10-28	Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
IL221873A (en)	2016-05-31	Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
BR112012001344A2 (pt)	2016-03-15	derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
FR2967674B1 (fr)	2012-12-14	Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
ZA201401678B (en)	2015-04-29	Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
BR112013003530A2 (pt)	2016-06-28	''produto farmacêutico, kit, uso e preparações''
EP2532652A4 (en)	2013-11-13	THERAPEUTIC AGENT AGAINST HEPATITIS C
CL2014003325A1 (es)	2015-04-24	Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
FR2954943B1 (fr)	2013-03-01	Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
IT1400837B1 (it)	2013-07-02	Metodo per la preparazione e uso di biocidi arricchiti in radicali attivi prima dell'uso.
EP2533752B8 (de)	2021-06-16	Zubereitungen zur stabilisierung / aufbau der textur lebender gewebe wie haut, und deren anwendungen
BRPI0923886A2 (pt)	2015-07-28	"uso de cloreto de amônio em terapia"